Evaluation & Management of Metabolic Bone Disease in Kidney Transplant

Status Completed

Clinical Trial Summary

There is a well-documented increased risk for disordered mineral bone homeostasis in Kidney Transplant Recipients (KTRs) when compared to the general population, leading to a markedly increased risk for fragility fractures and their associated morbidity and mortality. A more uniform and rigorous evaluation of bone and mineral homeostasis,than is afforded to patients under "normal care", will result in better clinical outcomes in KTRs.

Clinical Trial Description

The aim is to comprehensively characterize the mineral metabolism and skeletal phenotype in kidney transplant recipients (KTRs) to being to identify risk factors for post-kidney transplant mineral bone disease (PKT-MBD); and to evaluate whether treatment of abnormalities in these parameters will improve skeletal health as quantified by bone mineral density (BMD), bone turnover markers (rate of skeletal remodeling) and Osteoprobe (a direct index of bone quality using reference point indentation technology. Participants in the rigorous evaluation arm will be followed with a) Mineral metabolism: blood calcium, phosphorus, parathyroid hormone (PTH), 25(OH) vitamin D; b) Bone turnover markers: bone-specific alkaline phosphatase, cross-linked C-telopeptide of type I collagen (CTx), and N-terminal propeptide of type I collagen (PINP); c)Bone Mineral Density using a Dual energy x-ray absorptiometry which is the standard method by which bone mass is measured clinically. NOTE: The use of the Osteoprobe was discontinued on 9/5/19 due to safety concerns from the FDA about the device in other trials/other sites. The Control Cohort is essentially an historical control group who will have received standard of care for the 18 months ending just prior to the enrollment of our Intervention Cohort. A coincident Control Cohort will not be used because knowledge of the additional data to be collected in the Control Cohort will undoubtedly influence their care by their attending nephrologists and surgeons. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03958409
Study type	Interventional
Source	Yale University
Contact
Status	Completed
Phase	N/A
Start date	December 12, 2018
Completion date	December 2, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04369456` - Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients	N/A
Recruiting	`NCT06001320` - De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip	Early Phase 1
Withdrawn	`NCT04560582` - Immunosuppression Reduction in Failed Allograft Guided by cfDNA
Not yet recruiting	`NCT05782543` - Renal Ex Vivo Warm Advanced Resuscitation Through Machine Perfusion	N/A
Completed	`NCT03996551` - ExeRTiOn2- The Weight Gain Prevention Exercise in Renal Transplant Online Study	N/A
Recruiting	`NCT05081141` - HHV8 and Solid Organ Transplantation
Recruiting	`NCT04508907` - A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients	Phase 4
Not yet recruiting	`NCT06025240` - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Recruiting	`NCT04713774` - Bone Density and Vascular Calcifications Evolution After Renal Transplant
Active, not recruiting	`NCT05483725` - Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
Recruiting	`NCT06095492` - Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus	N/A
Active, not recruiting	`NCT04207177` - Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects	Phase 4
Recruiting	`NCT03410654` - Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.	Early Phase 1
Completed	`NCT03373266` - Serun Fluoride and Kidney Transplant	Phase 2
Completed	`NCT04835948` - Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation
Not yet recruiting	`NCT04514666` - VOCs in Kidney and Liver Transplants	N/A
Recruiting	`NCT03373500` - Effect of Dietary Salt Reduction on Blood Pressure in Kidney Transplant Recipients	N/A
Recruiting	`NCT05900401` - Delayed Tolerance Through Mixed Chimerism	Phase 1/Phase 2
Not yet recruiting	`NCT05166460` - Novel Cooling Device for the Elimination of Warm Ischemia During Renal Transplantation	N/A
Recruiting	`NCT05977387` - Pediatric Kidney Transplant

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation and Management of Metabolic Bone Disease in Kidney Transplant Recipients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms